Science & Technology
Fri, March 11, 2011Thu, March 10, 2011Wed, March 9, 2011Tue, March 8, 2011Mon, March 7, 2011Sun, March 6, 2011Sat, March 5, 2011Fri, March 4, 2011Thu, March 3, 2011Wed, March 2, 2011Tue, March 1, 2011iCAD to Host Fourth Quarter and Full Year 2010 Financial Results Conference Call on Thursday, March 24, 2011
//science-technology.news-articles.net/content/2 .. s-conference-call-on-thursday-march-24-2011.html
Published in Science and Technology on Monday, March 7th 2011 at 11:45 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that the Company will release financial results for the fourth quarter and fiscal year ended December 31, 2010, following the close of the market on Wednesday, March 23, 2011.
Ken Ferry, President and Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will host a conference call for investors beginning at 10:00 a.m. Eastern Time on Thursday, March 24, 2011 to discuss fourth quarter and full year 2010 financial results and to answer questions.
Shareholders and other interested parties may participate in the conference call by dialing 800-299-7635 (domestic) or 617-786-2901 (international) and entering passcode 52212023 a few minutes before 10:00 a.m. ET on Thursday, March 24, 2011. The call will also be broadcast live on the Internet at [ www.streetevents.com ], [ www.fulldisclosure.com ] and [ www.icadmed.com ].
A replay of the conference call will be accessible two hours after its completion through March 31, 2011 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode90176316. The call will also be archived for 90 days at [ www.streetevents.com ], [ www.fulldisclosure.com ] and [ www.icadmed.com ].
About iCAD
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent® eBxa" electronic brachytherapy system (eBx). Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit [ www.icadmed.com ].
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Companya™s filings with the Securities and Exchange Commission. The words abelievea, ademonstratea, aintenda, aexpecta, aestimatea, aanticipatea, alikelya, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
